Back to top

Analyst Blog

Shares of  Pacira Pharmaceuticals, Inc. (PCRX - Snapshot Report) soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.

We note that Pacira initiated a public offering of its common stock worth $100 million earlier in the week.

Pacira expects net proceeds of approximately $96.0 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses.

Moreover, underwriters have been granted an option to purchase an additional 240,000 shares, with a 30-day window to do so.  The offering is expected to close by Apr 14, 2014.

We are encouraged by the recent bout of positive news at Pacira. Pacira’s lead drug Exparel, is approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce post-surgical analgesia.

Exparel was launched in Apr 2012 and demand has been robust ever since. Net Exparel revenues were $76.2 million in 2013. Since its launch, 2,106 customers have ordered Exparel (data as of Dec 31, 2013).

Pacira recently signed a strategic co-production partnership deal with Patheon. As per the partnership agreement, Exparel will be manufactured and packaged at Patheon’s facility in the U.K. Further, Patheon will construct the dedicated manufacturing suites, install and validate the manufacturing equipments and manufacture Exparel.

Pacira is working to expand the manufacturing capacity of Exparel to meet the growing demand for the drug. Last month, the FDA approved an additional manufacturing suite (Suite C) for Exparel.

The site at Patheon will be designed to mirror the recently approved Suite C manufacturing facility. We expect the company to use the funds for further commercilization of Exparel.

Pacira carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the pharma sector may consider companies like Salix Pharmaceuticals (SLXP - Analyst Report), Sucampo Pharmaceuticals (SCMP - Snapshot Report) and Immunogen Inc. (IMGN - Snapshot Report).

Read the Full Research Report on SCMP
Read the Full Research Report on SLXP
Read the Full Research Report on PCRX
Read the Full Research Report on IMGN


Zacks Investment Research

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%